Clinical trial
UARK 2003-33, Total Therapy III
NCT00081939 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00081939 |
|---|---|
| Title | UARK 2003-33, Total Therapy III |
| Official title | A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance |
| Lead sponsor | University of Arkansas, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Velcade, Thalidomide |
| Enrollment | 303 |
| Start date | Jan 1, 2004 |
| Primary completion | Sep 1, 2014 |
| Completion | Sep 1, 2014 |
| First posted | Apr 29, 2004 |
| Last update posted | Oct 17, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: